{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:39:04Z","timestamp":1792931944899,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA021765"],"award-info":[{"award-number":["P30CA021765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41409-024-02197-3","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T11:02:25Z","timestamp":1705316545000},"page":"451-458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP\/EBMT study"],"prefix":"10.1038","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-2081","authenticated-orcid":false,"given":"Akshay","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9102-4427","authenticated-orcid":false,"given":"Jacques-Emmanuel","family":"Galimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angharad","family":"Pryce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-6549","authenticated-orcid":false,"given":"Senthil Velan","family":"Bhoopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Dalissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Hugues","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Jubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Mirci-Danicar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Kitra-Roussou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9257-900X","authenticated-orcid":false,"given":"Franca","family":"Fagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3136-6270","authenticated-orcid":false,"given":"Fanny","family":"Rialland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Biffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6046-8428","authenticated-orcid":false,"given":"Robert F.","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-5709","authenticated-orcid":false,"given":"G\u00e9rard","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9145-3691","authenticated-orcid":false,"given":"Francesco Paolo","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-5611","authenticated-orcid":false,"given":"Ali","family":"Al-Ahmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelghani","family":"Tbakhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline L.","family":"Furness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Sedlacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Bodova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5715-501X","authenticated-orcid":false,"given":"Maura","family":"Faraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1447-7286","authenticated-orcid":false,"given":"Katharina","family":"Kleinschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8363-1622","authenticated-orcid":false,"given":"Arnaud","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2033-1125","authenticated-orcid":false,"given":"Neel S.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-5799","authenticated-orcid":false,"given":"Krzysztof","family":"Kalwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1070-8486","authenticated-orcid":false,"given":"Selim","family":"Corbacioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"2197_CR1","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021011694","volume":"138","author":"JE Rubnitz","year":"2021","unstructured":"Rubnitz JE, Kaspers GJL. How I treat pediatric acute myeloid leukemia. Blood. 2021;138:1009\u201318.","journal-title":"Blood"},{"key":"2197_CR2","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","volume":"120","author":"MR Loken","year":"2012","unstructured":"Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children\u2019s Oncology Group. Blood. 2012;120:1581\u20138.","journal-title":"Blood"},{"key":"2197_CR3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","volume":"29","author":"CH Pui","year":"2011","unstructured":"Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29:551\u201365.","journal-title":"J Clin Oncol"},{"key":"2197_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40272-016-0200-6","volume":"19","author":"JE Rubnitz","year":"2017","unstructured":"Rubnitz JE. Current management of childhood acute myeloid leukemia. Paediatr Drugs. 2017;19:1\u201310.","journal-title":"Paediatr Drugs"},{"key":"2197_CR5","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","volume":"114","author":"BV Balgobind","year":"2009","unstructured":"Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114:2489\u201396.","journal-title":"Blood"},{"key":"2197_CR6","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1200\/JCO.2007.13.5244","volume":"26","author":"JT Horan","year":"2008","unstructured":"Horan JT, Alonzo TA, Lyman GH, Gerbing RB, Lange BJ, Ravindranath Y, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children\u2019s Oncology Group. J Clin Oncol. 2008;26:5797\u2013801.","journal-title":"J Clin Oncol"},{"key":"2197_CR7","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1200\/JCO.20.03048","volume":"39","author":"JA Pollard","year":"2021","unstructured":"Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, et al. Gemtuzumab Ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the Phase III children\u2019s oncology group trial AAML0531. J Clin Oncol. 2021;39:3149\u201360.","journal-title":"J Clin Oncol"},{"key":"2197_CR8","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.22.02120","volume":"41","author":"RE van Weelderen","year":"2023","unstructured":"van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, et al. Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia: a study by the international Berlin-Frankfurt-Munster Study Group. J Clin Oncol. 2023;41:2963\u201374.","journal-title":"J Clin Oncol"},{"key":"2197_CR9","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1182\/blood-2013-02-485524","volume":"122","author":"EA Coenen","year":"2013","unstructured":"Coenen EA, Zwaan CM, Reinhardt D, Harrison CJ, Haas OA, de Haas V, et al. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood. 2013;122:2704\u201313.","journal-title":"Blood"},{"key":"2197_CR10","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","volume":"28","author":"CJ Harrison","year":"2010","unstructured":"Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010;28:2674\u201381.","journal-title":"J Clin Oncol"},{"key":"2197_CR11","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1097\/HS9.0000000000000031","volume":"2","author":"A Marceau-Renaut","year":"2018","unstructured":"Marceau-Renaut A, Duployez N, Ducourneau B, Labopin M, Petit A, Rousseau A, et al. Molecular profiling defines distinct prognostic subgroups in childhood AML: a report from the french ELAM02 Study Group. Hemasphere. 2018;2:e31.","journal-title":"Hemasphere"},{"key":"2197_CR12","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/blood-2012-11-469825","volume":"121","author":"R Masetti","year":"2013","unstructured":"Masetti R, Pigazzi M, Togni M, Astolfi A, Indio V, Manara E, et al. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood. 2013;121:3469\u201372.","journal-title":"Blood"},{"key":"2197_CR13","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1200\/JCO.2009.25.6321","volume":"28","author":"C von Neuhoff","year":"2010","unstructured":"von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28:2682\u20139.","journal-title":"J Clin Oncol"},{"key":"2197_CR14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.bbmt.2007.01.079","volume":"13","author":"P Armand","year":"2007","unstructured":"Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM, et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007;13:655\u201364.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2197_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.bbmt.2011.07.024","volume":"18","author":"P Armand","year":"2012","unstructured":"Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, et al. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2012;18:280\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2197_CR16","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/bmt.2012.55","volume":"47","author":"P Chevallier","year":"2012","unstructured":"Chevallier P, Labopin M, Milpied N, Cornelissen JJ, Blaise D, Petersen E, et al. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2012;47:1442\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"2197_CR17","first-page":"2931","volume":"90","author":"A Ferrant","year":"1997","unstructured":"Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 1997;90:2931\u20138.","journal-title":"Blood"},{"key":"2197_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1532\/IJH97.03166","volume":"79","author":"H Ogawa","year":"2004","unstructured":"Ogawa H, Ikegame K, Kawakami M, Takahashi S, Sakamaki H, Karasuno T, et al. Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation. Int J Hematol. 2004;79:495\u2013500.","journal-title":"Int J Hematol"},{"key":"2197_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/bmt.2016.293","volume":"52","author":"AL Alloin","year":"2017","unstructured":"Alloin AL, Leverger G, Dalle JH, Galambrun C, Bertrand Y, Baruchel A, et al. Cytogenetics and outcome of allogeneic transplantation in first remission of acute myeloid leukemia: the French pediatric experience. Bone Marrow Transplant. 2017;52:516\u201321.","journal-title":"Bone Marrow Transplant"},{"key":"2197_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1053\/bbmt.2002.v8.pm12234169","volume":"8","author":"Y Chalandon","year":"2002","unstructured":"Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ, et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2002;8:435\u201343.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2197_CR21","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1182\/blood-2010-04-278317","volume":"116","author":"V Gupta","year":"2010","unstructured":"Gupta V, Tallman MS, He W, Logan BR, Copelan E, Gale RP, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood. 2010;116:1839\u201348.","journal-title":"Blood"},{"key":"2197_CR22","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1200\/JCO.2007.15.5184","volume":"26","author":"J Schetelig","year":"2008","unstructured":"Schetelig J, Bornhauser M, Schmid C, Hertenstein B, Schwerdtfeger R, Martin H, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol. 2008;26:5183\u201391.","journal-title":"J Clin Oncol"},{"key":"2197_CR23","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/leu.2010.102","volume":"24","author":"RB Walter","year":"2010","unstructured":"Walter RB, Pagel JM, Gooley TA, Petersdorf EW, Sorror ML, Woolfrey AE, et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia. 2010;24:1276\u201382.","journal-title":"Leukemia"},{"key":"2197_CR24","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/bmt.2012.159","volume":"48","author":"M Yanada","year":"2013","unstructured":"Yanada M, Kurosawa S, Yamaguchi T, Uchida N, Miyawaki S, Kanamori H, et al. Effect of related donor availability on outcome of AML in the context of related and unrelated hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48:390\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"2197_CR25","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","volume":"31","author":"A Bashey","year":"2013","unstructured":"Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310\u20136.","journal-title":"J Clin Oncol"},{"key":"2197_CR26","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood-2018-07-861575","volume":"132","author":"A Bertaina","year":"2018","unstructured":"Bertaina A, Zecca M, Buldini B, Sacchi N, Algeri M, Saglio F, et al. Unrelated donor vs HLA-haploidentical alpha\/beta T-cell- and B-cell-depleted HSCT in children with acute leukemia. Blood. 2018;132:2594\u2013607.","journal-title":"Blood"},{"key":"2197_CR27","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033\u201340.","journal-title":"Blood"},{"key":"2197_CR28","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.bbmt.2016.02.002","volume":"22","author":"M Berger","year":"2016","unstructured":"Berger M, Lanino E, Cesaro S, Zecca M, Vassallo E, Faraci M, et al. Feasibility and outcome of haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide for children and adolescents with hematologic malignancies: an AIEOP-GITMO retrospective multicenter study. Biol Blood Marrow Transplant. 2016;22:902\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2197_CR29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","volume":"130","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Merli P, Pagliara D, Li Pira G, Falco M, Pende D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion. Blood. 2017;130:677\u201385.","journal-title":"Blood"},{"key":"2197_CR30","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1200\/JCO.2012.43.4738","volume":"30","author":"K Mrozek","year":"2012","unstructured":"Mrozek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30:4515\u201323.","journal-title":"J Clin Oncol"},{"key":"2197_CR31","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079\u201389.","journal-title":"N Engl J Med"},{"key":"2197_CR32","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","volume":"29","author":"C Rollig","year":"2011","unstructured":"Rollig C, Bornhauser M, Thiede C, Taube F, Kramer M, Mohr B, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29:2758\u201365.","journal-title":"J Clin Oncol"},{"key":"2197_CR33","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/s41409-021-01448-x","volume":"56","author":"A Sharma","year":"2021","unstructured":"Sharma A, Huang S, Li Y, Brooke RJ, Ahmed I, Allewelt HB, et al. Outcomes of pediatric patients with therapy-related myeloid neoplasms. Bone Marrow Transplant. 2021;56:2997\u20133007.","journal-title":"Bone Marrow Transplant"},{"key":"2197_CR34","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1182\/blood-2013-10-535716","volume":"123","author":"M Bitan","year":"2014","unstructured":"Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, et al. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014;123:1615\u201320.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02197-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02197-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02197-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T08:02:57Z","timestamp":1712217777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02197-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2197"],"URL":"https:\/\/doi.org\/10.1038\/s41409-024-02197-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"assertion":[{"value":"29 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AS has received consultant fees from Spotlight Therapeutics, Medexus Inc., Vertex Pharmaceuticals, Sangamo Therapeutics, and Editas Medicine. He is a medical monitor for an RCI BMT CSIDE clinical trial for which he receives financial compensation. He has also received research funding from CRISPR Therapeutics and honoraria from Vindico Medical Education. AS is the St. Jude Children\u2019s Research Hospital site principal investigator of clinical trials for genome editing of sickle cell disease sponsored by Vertex Pharmaceuticals\/CRISPR Therapeutics (NCT03745287), Novartis Pharmaceuticals (NCT04443907), and Beam Therapeutics (NCT05456880). The industry sponsors provide funding for the clinical trial, which includes salary support paid to AS\u2019s institution. AS has no direct financial interest in these therapies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}